Luke Halpern is an assistant editor with Pharmacy Times. Luke wrote for Pharmacy Times in the summer of 2023, and assumed a full-time role in June 2024. His work has been featured in Pharmacy Times and the American Journal of Managed Care. He graduated from the University of Massachusetts, Amherst in May 2024.
Expert: Community Pharmacies Remain Pillar of Patient Care
August 6th 2024Chris Peshek of Discount Drug Mart discusses the importance of community pharmacies and the process of building relationships with patients, and how a profession in the field can be rewarding for those seeking to pursue it.
Read More
Severe Pemphigus Vulgaris Successfully Treated With Intravenous Immunoglobulin
July 17th 2024A patient with severe and recurrent pemphigus vulgaris achieved lasting remission with a novel intravenous immunoglobulin preparation that had the added benefit of reducing treatment-related side effects.
Read More
Comparison Shows Eligibility for Vericiguat Wider Than Expected for Heart Failure
July 17th 2024Investigators compared the criteria for eligibility in the VICTORIA trial with guideline and label criterion, finding a wider than expected population with heart failure were eligible for vericiguat therapy.
Read More
Expert: Availability of OTC Naloxone in Stores, Pharmacies Will Lead to Greater Uptake
July 16th 2024Allison Burns discusses how pharmacists should prepare and educate themselves regarding OTC naloxone, and the steps that can be taken in stores and pharmacies to ensure OTC naloxone is visible and available.
Read More
Heterogeneity Observed in Reporting on Drug-Drug Interactions With Proton Pump Inhibitors
July 12th 2024An analysis of interaction checkers and product summaries revealed large differences in the consistency and reliability of providing accurate information on potential drug-drug interactions.
Read More
Common Surgical Procedures Account for High Share of Opioid Prescriptions in Children and Adults
July 11th 2024In pediatric and adult patients, the top 3 surgical procedures accounted for the highest share of opioid prescriptions, indicating a need for better opioid prescription management and greater awareness of the possible opioid-related adverse events that can stem from prescriptions of the drug.
Read More
FTC Intends to Sue Biggest Pharmacy Benefit Managers for Unfair Negotiating Tactics
July 11th 2024In a follow-up to the interim FTC report documenting the business practices of PBMs and the power they hold in the pharmaceutical industry, the Commission now seeks to sue the 3 largest PBMs in the country for driving up the price of insulin and other essential drugs.
Read More
High-Dose Intravenous Immunoglobulin Responsive to Platelet-Activating Anti-PF4 Disorder
July 11th 2024Intravenous immunoglobulin was effective as an adjunctive treatment to anticoagulation in a patient with post-viral platelet-activating anti-PF4 disorder, indicating the need for accurate diagnosis and treatment selection.
Read More